INSM News and Press, Insmed Inc. From 05/28/24

2024-05-28 16:00:07 ET Andrea Tan from Goldman Sachs issued a price target of $74.00 for INSM on 2024-05-28 13:27:00. The adjusted price target was set to $74.00. At the time of the announcement, INSM was trading at $46.39. The overall price target consensus is at $46.67...

2024-05-28 14:04:21 ET More on Mid-day movers & stock Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage Semler Scientific, Inc. (SMLR) Q1 2024 Earnings Call Transcript G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript A...

2024-05-28 12:10:00 ET Summary Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ratio but substantial long-term debt. Peak r...

Insmed Incorporated (NASDAQ: INSM) is one of today's top gainers. The company's shares have moved 111.43% on the day to $46.49. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for t...

2024-05-28 10:00:33 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 121.3% to $0.3941 on volume of 248,629,940 shares Sharps Technology Inc. (STSS) rose 184.6% to $0.61 on volume of 114,390,080 shares Crown Electrokinetics Corp. (CRKN) rose 31.2% to $0.1325 on volume ...

2024-05-28 07:08:55 ET Shares of Insmed Inc (NASDAQ: INSM) more than doubled on Tuesday after the biopharmaceutical firm reported positive results for its ASPEN study. Insmed stock soars on topline results from ASPEN study The Phase 3 trial evaluated “efficacy, safety, an...

2024-05-28 06:54:16 ET More on Insmed Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Insmed Historical earnings data for Insmed Financial information for Insmed Read the full article on Seeking Alpha ...

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis PR Newswire —Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Redu...

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis PR Newswire —Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024 , at 8:00 am ET— BRIDGEWATER, N.J. , M...